Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2025
NICE’s backing of the prostate cancer drug abiraterone could help thousands and save the NHS millions
30 October 2025 - Today we’ve published final draft guidance recommending abiraterone and its generic variants in combination with androgen ...
Posted by Michael Wonder on 24 Oct 2025
Up to 6,000 patients to benefit from NICE-approved life-extending prostate cancer drug
24 October 2025 - People living with metastatic prostate cancer in England will gain access to a new treatment combination from ...
Posted by Michael Wonder on 22 Oct 2025
Sarilumab for the treatment of children/adolescents 2-17 years of age with polyarticular or oligoarticular juvenile idiopathic arthritis
22 October 2025 - NICE is unable to make a recommendation on the use of sarilumab (Kevzara) for the treatment of ...
Posted by Michael Wonder on 22 Oct 2025
Clascoterone for the treatment of patients 12 years of age and older with acne vulgaris
22 October 2025 - NICE is unable to make a recommendation on the use of clascoterone (Winlevi) for the treatment of patients ...
Posted by Michael Wonder on 17 Oct 2025
First HIV prevention injection for people unable to have daily PrEP recommended
17 October 2025 - A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small ...
Posted by Michael Wonder on 17 Oct 2025
Same time decisions on licensing and value - what pharmaceutical companies need to know
10 October 2025 - Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and ...
Posted by Michael Wonder on 11 Oct 2025
MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule
10 October 2025 - Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them ...
Posted by Michael Wonder on 17 Sep 2025
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
16 September 2025 - Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung ...
Posted by Michael Wonder on 11 Sep 2025
Methods used in early value assessments for NICE: a scoping review
8 September 2025 - NICE in England introduced early value assessments as an evidence-based method of accelerating access to promising ...
Posted by Michael Wonder on 22 Aug 2025
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
21 August 2025 - NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant ...
Posted by Michael Wonder on 14 Aug 2025
Final decision on cerliponase alfa for Batten disease treatment confirmed
14 August 2025 - In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (Brineura; BioMarin) ...
Posted by Michael Wonder on 06 Aug 2025
NICE approves first immunotherapy combination for endometrial cancer
6 August 2025 - Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, ...
Posted by Michael Wonder on 02 Aug 2025
Seladelpar lysine dihydrate for the treatment of patients with primary biliary cholangitis
30 July 2025 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 01 Aug 2025
Serplulimab in combination with carboplatin and etoposide phosphate for the first-line treatment of patients with extensive-stage small-cell lung cancer
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2025
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency
30 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...